Flag of the European Union EU Clinical Trials Register Help

Clinical trials for liquid placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    208 result(s) found for: liquid placebo. Displaying page 11 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11 
    EudraCT Number: 2004-003236-59 Sponsor Protocol Number: LRX –TRIUMPH-001 Start Date*: 2005-06-30
    Sponsor Name:United Therapeutics Corporation
    Full Title: Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.
    Medical condition: NYHA Class III and IV patients with severe Pulmonary Arterial Hypertension (PAH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) AT (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005536-17 Sponsor Protocol Number: UX007G-CL301 Start Date*: 2017-05-17
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1...
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10061032 Carbohydrate transport disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005911-82 Sponsor Protocol Number: AL0506st Start Date*: 2007-04-02
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter, placebo-controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children w...
    Medical condition: IgE-mediated allergic disease manifested as symptoms of allergic rhinitis/rhinoconjunctivitis with or without allergic bronchial asthma (GINA I und II) triggered by grass pollen allergens.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003543-30 Sponsor Protocol Number: EB93 Start Date*: 2012-08-24
    Sponsor Name:Emotional Brain BV
    Full Title: A double-blind, randomized, placebo-controlled, proof of concept study to investigate the differences between the combined administration of 0.5 mg sublingual testosterone and 10 mg buspirone and 1...
    Medical condition: Hypoactive Sexual Desire Disorder Sexual Interest/Arousal Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10037228 Psychosexual dysfunction with inhibited sexual desire LLT
    14.1 10037175 - Psychiatric disorders 10059272 Sexual desire decreased LLT
    14.1 10037175 - Psychiatric disorders 10040465 Sexual arousal decreased LLT
    14.1 10037175 - Psychiatric disorders 10058929 Disturbance in sexual arousal PT
    14.1 10037175 - Psychiatric disorders 10040470 Sexual desire disorders HLT
    14.1 10037175 - Psychiatric disorders 10040466 Sexual arousal disorders HLT
    14.1 10037175 - Psychiatric disorders 10020933 Hypoactive sexual desire disorder LLT
    14.1 10038604 - Reproductive system and breast disorders 10062641 Female sexual arousal disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003298-10 Sponsor Protocol Number: C0524T08 Start Date*: 2006-06-07
    Sponsor Name:Centocor BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis
    Medical condition: Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-003295-10 Sponsor Protocol Number: C0524T05 Start Date*: 2006-05-17
    Sponsor Name:Centocor BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve Subjects with Acti...
    Medical condition: Active Rheumatoid Arthritis (methotrexate [MTX]-naïve)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001848-21 Sponsor Protocol Number: ALRN-6924-1-03 Start Date*: 2019-09-12
    Sponsor Name:Aileron Therapeutics, Inc.
    Full Title: A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
    Medical condition: Small Cell Lung Cancer and Non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023986-23 Sponsor Protocol Number: LF-0802 Start Date*: 2011-05-27
    Sponsor Name:Agennix Incorporated
    Full Title: OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis
    Medical condition: Severe Sepsis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 01:28:39 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA